Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 25;13(7):1228.
doi: 10.3390/v13071228.

Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and -2

Lauren A Sadowski  1 , Rista Upadhyay  1   2 , Zachary W Greeley  1 , Barry J Margulies  1   3
Affiliations
Review

Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and -2

Lauren A Sadowski et al. Viruses. .

Abstract

Herpes simplex viruses-1 and -2 (HSV-1 and -2) are two of the three human alphaherpesviruses that cause infections worldwide. Since both viruses can be acquired in the absence of visible signs and symptoms, yet still result in lifelong infection, it is imperative that we provide interventions to keep them at bay, especially in immunocompromised patients. While numerous experimental vaccines are under consideration, current intervention consists solely of antiviral chemotherapeutic agents. This review explores all of the clinically approved drugs used to prevent the worst sequelae of recurrent outbreaks by these viruses.

Keywords: HSV-1; HSV-2; acyclovir; amenamevir; cidofovir; docosanol; foscarnet; ganciclovir; nelfinavir; vidarabine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Nucleoside analogs.
Figure 2
Figure 2
Nucleotide analogs.
Figure 3
Figure 3
Foscarnet.
Figure 4
Figure 4
Helicase–primase inhibitors.
Figure 5
Figure 5
n-Docosanol.
Figure 6
Figure 6
Nelfinavir.
See this image and copyright information in PMC

References

    1. Kaufman H., Martola E.L., Dohlman C. Use of 5-iodo-2′-deoxyuridine (IDU) in treatment of herpes simplex keratitis. Arch. Ophthalmol. 1962;68:235–239. doi: 10.1001/archopht.1962.00960030239015. - DOI - PubMed
    1. Kaufman H.E. Clinical cure of herpes simplex keratitis by 5-iodo-2-deoxyuridine. Proc. Soc. Exp. Biol. Med. 1962;109:251–252. doi: 10.3181/00379727-109-27169. - DOI - PubMed
    1. Roizman B., Knipe D.M., Whitley R.J. Herpes Simplex Viruses. In: Knipe D.M., Howley P.M., Cohen J.I., Griffin D.E., Lamb R.A., Martin M.A., Racaniello V.R., Roizman B., editors. Fields Virology. 6th ed. Wolters Kluwer/Lippincott Williams & Wilkins; Philadelphia, PA, USA: 2013. pp. 1823–1897.
    1. Looker K.J., Garnett G.P. A systematic review of the epidemiology and interaction of herpes simplex virus types 1 and 2. Sex. Transm. Infect. 2005;81:103–107. doi: 10.1136/sti.2004.012039. - DOI - PMC - PubMed
    1. Kalu N.N., Desai P.J., Shirley C.M., Gibson W., Dennis P.A., Ambinder R.F. Nelfinavir inhibits maturation and export of herpes simplex virus 1. J. Virol. 2014;88:5455–5461. doi: 10.1128/JVI.03790-13. - DOI - PMC - PubMed

MeSH terms

Substances